| SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech |
NCT04556539: Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer |
|
|
| Recruiting | 2 | 104 | RoW | SC10914 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Advanced Ovarian Cancer | 12/21 | 12/22 | | |
NCT04556292: A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients |
|
|
| Recruiting | 2 | 78 | RoW | SC10914 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation | 03/22 | 08/22 | | |
NCT04486937: SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation |
|
|
| Not yet recruiting | 1/2 | 90 | NA | S410914 tablet | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Metastatic Castration Resistant Prostate Cancer | 12/21 | 06/22 | | |
CTR20201968: Phase I clinical study on the effect of food on the pharmacokinetics of SC10914 |
|
|
| Completed | 1 | 18 | China | SC10914 - Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech | Jiangxi Qingfeng Pharmaceutical Co., Ltd./Shanghai Dino Pharmaceutical Technology Co., Ltd. | Advanced solid tumors | | | | |
| Xiyanping / Jiangxi Qingfeng Pharma |
NCT04296383: Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia |
|
|
| Not yet recruiting | N/A | 450 | NA | Azithromycin plus Xiyanping injection, Azithromycin | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Mycoplasma Pneumoniae Pneumonia | 08/21 | 08/22 | | |
QF-XYP2021-1, NCT04926506: Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children |
|
|
| Not yet recruiting | N/A | 80 | NA | Xiyanping injection | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Acute Bronchitis in Children | 09/22 | 12/22 | | |
| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma |
NCT05474755: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection |
|
|
| Completed | 3 | 591 | RoW | GP681 40mg, Placebo | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 04/23 | 10/23 | | |
NCT06573008: Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications |
|
|
| Not yet recruiting | 3 | 328 | NA | GP681 40mg, GP681 Simulant | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza, Human | 12/25 | 12/25 | | |
NCT06574503: Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza |
|
|
| Not yet recruiting | 3 | 748 | NA | GP681 40mg, GP681 Simulant | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 07/27 | 12/27 | | |
NCT05789342: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers |
|
|
| Completed | 1 | 54 | RoW | GP681, Rosuvastatin, Digoxin, Itraconazole, Oseltamivir | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Volunteers | 09/23 | 10/23 | | |
NCT05814926: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers |
|
|
| Completed | 1 | 24 | RoW | GP681 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Volunteers, Hepatic Impairment | 08/23 | 10/23 | | |
NCT06643156: Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension |
|
|
| Recruiting | 1 | 40 | RoW | GP681 10mg/20mg/40mg | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 02/25 | 03/25 | | |
NCT06678542: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects |
|
|
| Not yet recruiting | 1 | 36 | NA | GP681 tablet, Reference treatment, GP681 Powder for Oral Suspension, Test Treatment | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Participants | 12/24 | 01/25 | | |
| BR790 / Jiangxi Qingfeng Pharma |
NCT05505877: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 160 | RoW | BR790+Tislelizumab | Shanghai Gopherwood Biotech Co., Ltd. | Advanced Solid Tumor | 10/24 | 12/24 | | |
NCT05715398: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 1/2 | 90 | NA | BR790+anlotinib | Shanghai Gopherwood Biotech Co., Ltd. | Non-Small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT04891653: A Phase I Study of BR790 in Subjects With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 48 | NA | BR790 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 06/23 | 12/23 | | |
